JP2018504584A - 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 - Google Patents

過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 Download PDF

Info

Publication number
JP2018504584A
JP2018504584A JP2017529256A JP2017529256A JP2018504584A JP 2018504584 A JP2018504584 A JP 2018504584A JP 2017529256 A JP2017529256 A JP 2017529256A JP 2017529256 A JP2017529256 A JP 2017529256A JP 2018504584 A JP2018504584 A JP 2018504584A
Authority
JP
Japan
Prior art keywords
integrin
level
subject
vedolizumab
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017529256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504584A5 (enExample
Inventor
シャラット シング，
シャラット シング，
アンジャリ ジャイン，
アンジャリ ジャイン，
ヴェンカッテスワル コンドラグンタ，
ヴェンカッテスワル コンドラグンタ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2018504584A publication Critical patent/JP2018504584A/ja
Publication of JP2018504584A5 publication Critical patent/JP2018504584A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017529256A 2014-12-02 2015-12-02 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 Pending JP2018504584A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086549P 2014-12-02 2014-12-02
US62/086,549 2014-12-02
US201562157903P 2015-05-06 2015-05-06
US62/157,903 2015-05-06
PCT/IB2015/059303 WO2016088068A1 (en) 2014-12-02 2015-12-02 Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease

Publications (2)

Publication Number Publication Date
JP2018504584A true JP2018504584A (ja) 2018-02-15
JP2018504584A5 JP2018504584A5 (enExample) 2019-01-17

Family

ID=54849673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529256A Pending JP2018504584A (ja) 2014-12-02 2015-12-02 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法

Country Status (7)

Country Link
US (1) US10324088B2 (enExample)
EP (1) EP3227685A1 (enExample)
JP (1) JP2018504584A (enExample)
CA (1) CA2969326A1 (enExample)
HK (1) HK1244881A1 (enExample)
MX (1) MX2017006959A (enExample)
WO (1) WO2016088068A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018349287A1 (en) * 2017-10-10 2020-05-07 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
EP3543692A1 (en) * 2018-03-22 2019-09-25 Friedrich-Alexander-Universität Erlangen-Nürnberg Adhesion assay
WO2020226498A1 (en) 2019-05-07 2020-11-12 Rijksuniversiteit Groningen Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin.
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
WO2014055824A1 (en) * 2012-10-05 2014-04-10 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
JP2014517279A (ja) * 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
WO2014160753A1 (en) * 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014188378A1 (en) * 2013-05-24 2014-11-27 Nestec S.A. Pathway specific markers for diagnosing irritable bowel syndrome

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
DE69424700T2 (de) 1993-03-10 2000-11-09 Cedars-Sinai Medical Center, Los Angeles Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
WO2005041896A2 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
US20060019410A1 (en) 2004-07-21 2006-01-26 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
CN102124344B (zh) * 2008-05-16 2015-04-01 霍夫曼-拉罗奇有限公司 生物标记用于评估β7整联蛋白拮抗剂治疗胃肠道炎性病症的用途
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
HRP20241666T1 (hr) * 2010-10-25 2025-02-14 Biogen Ma Inc. Metode za određivanje razlika u alfa-4 integrinskoj aktivnosti pomoću korelacijskih razlika u razinama svcam i/ili smadcam
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
JP2014517279A (ja) * 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
WO2013059732A1 (en) * 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
WO2014055824A1 (en) * 2012-10-05 2014-04-10 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2014160753A1 (en) * 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014188378A1 (en) * 2013-05-24 2014-11-27 Nestec S.A. Pathway specific markers for diagnosing irritable bowel syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAM J. SANDBORN, BRIAN G. FEAGAN, ET AL.: "Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 369, JPN6019040077, 22 August 2013 (2013-08-22), GB, pages 711 - 721, ISSN: 0004272748 *

Also Published As

Publication number Publication date
MX2017006959A (es) 2017-08-10
EP3227685A1 (en) 2017-10-11
US10324088B2 (en) 2019-06-18
WO2016088068A1 (en) 2016-06-09
US20170254806A1 (en) 2017-09-07
CA2969326A1 (en) 2016-06-09
HK1244881A1 (zh) 2018-08-17

Similar Documents

Publication Publication Date Title
Roda et al. Crohn’s disease
US8715943B2 (en) Methods for improving inflammatory bowel disease diagnosis
US10324088B2 (en) Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
US20130203053A1 (en) Methods for improving inflammatory bowel disease diagnosis
JP2018506528A5 (enExample)
Ng et al. Unmet needs in psoriatic arthritis
JP2023145731A (ja) ベドリズマブ処置をモニタリングするための方法
US11199534B2 (en) Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US9835632B2 (en) Biomarker panel for assessment of mucosal healing
WO2018102591A1 (en) Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis
EP3210027B1 (en) Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis
Nakamura et al. Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission
US20240044916A1 (en) Methods of monitoring inflammatory bowel diseases
HK1200933B (en) Methods for improving inflammatory bowel disease diagnosis
Berkeley et al. P-038 YI; Patterns of Hospitalization and Biologic Use in an Incident Cohort of Crohn’s Disease Patients
HK1249134B (zh) 结直肠癌相关疾病的生物标志物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181128

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20191127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210105